Biotech Director Bernard Coulie Granted Options as Septerna Approaches Clinical Phase

Rhea-AI Filing Summary

Director Bernard Coulie of Septerna received a stock option grant on June 17, 2025, according to a Form 4 filing. The grant consists of 16,623 stock options with an exercise price of $10.24 per share.

Key details of the option grant:

• Exercise Price: $10.24 per share
• Expiration Date: June 16, 2035
• Vesting Schedule: Full vesting upon the earlier of (i) June 17, 2026 or (ii) the next annual stockholders meeting
• Vesting Condition: Subject to continued service with the company

This appears to be a standard director compensation grant. The filing was signed by Jeffrey Finer as attorney-in-fact on June 20, 2025. The transaction represents direct ownership of the derivative securities.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Coulie Bernard

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,623	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 16,623 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coulie Bernard

(Last) (First) (Middle)

C/O SEPTERNA, INC.

250 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Septerna, Inc. [ SEPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.24	06/17/2025		A		16,623		(1)	06/16/2035	Common Stock	16,623	$0	16,623	D

Explanation of Responses:

1. The shares underlying the stock option will vest in full upon the earlier of (i) June 17, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

	/s/ Jeffrey Finer, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did Bernard Coulie receive from SEPN on June 17, 2025?

Bernard Coulie received 16,623 stock options from Septerna (SEPN) with an exercise price of $10.24 per share. These options were granted on June 17, 2025, and expire on June 16, 2035.

What are the vesting terms for SEPN director Bernard Coulie's June 2025 stock options?

The stock options will vest in full upon the earlier of either (i) June 17, 2026, or (ii) Septerna's next annual meeting of stockholders, subject to Bernard Coulie's continued service to the company through the vesting date.

What is Bernard Coulie's role at SEPN according to the Form 4?

According to the Form 4 filing, Bernard Coulie serves as a Director of Septerna, Inc. (SEPN). This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

How much did Bernard Coulie pay for the SEPN stock options granted in June 2025?

Bernard Coulie received the stock options at a price of $0, as indicated in the 'Price of Derivative Security' column of the Form 4 filing. However, when exercising these options in the future, he will need to pay the exercise price of $10.24 per share.